Indivior Pharmaceuticals, Inc. (INDV)
34.88
-0.81
(-2.27%)
USD |
NASDAQ |
Sep 18, 16:00
34.30
-0.58
(-1.66%)
After-Hours: 05:17
Indivior Pharmaceuticals Total Long Term Debt (Quarterly) : 500.00M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 500.00M |
| March 31, 2026 | 500.00M |
| December 31, 2025 | 341.00M |
| September 30, 2025 | 346.00M |
| June 30, 2025 | 355.00M |
| March 31, 2025 | 359.00M |
| December 31, 2024 | 365.00M |
| September 30, 2024 | 284.00M |
| June 30, 2024 | 281.00M |
| March 31, 2024 | 279.00M |
| December 31, 2023 | 282.00M |
| September 30, 2023 | 277.00M |
| June 30, 2023 | 281.00M |
| March 31, 2023 | 279.00M |
| December 31, 2022 | 277.00M |
| September 30, 2022 | 276.00M |
| June 30, 2022 | 280.00M |
| March 31, 2022 | 282.00M |
| December 31, 2021 | 286.00M |
| September 30, 2021 | 288.00M |
| June 30, 2021 | 290.00M |
| March 31, 2021 | 282.00M |
| December 31, 2020 | 285.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 283.00M |
| June 30, 2020 | 284.00M |
| March 31, 2020 | 285.00M |
| December 31, 2019 | 293.00M |
| September 30, 2019 | 292.00M |
| June 30, 2019 | 295.00M |
| March 31, 2019 | 297.00M |
| December 31, 2018 | 241.00M |
| September 30, 2018 | 324.00M |
| June 30, 2018 | 472.00M |
| March 31, 2018 | 478.00M |
| December 31, 2017 | 482.00M |
| September 30, 2017 | 341.00M |
| June 30, 2017 | 352.00M |
| March 31, 2017 | 423.00M |
| December 31, 2016 | 535.00M |
| September 30, 2016 | 546.00M |
| June 30, 2016 | 551.00M |
| March 31, 2016 | 542.00M |
| December 31, 2015 | 605.00M |
| September 30, 2015 | 528.00M |
| June 30, 2015 | 541.00M |
| March 31, 2015 | 669.00M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 29.43M |
| Liquidia Corp. | 182.90M |
| Eli Lilly & Co. | 49.62B |
| Collegium Pharmaceutical, Inc. | 1.216B |
| Bristol Myers Squibb Co. | 44.59B |